For patients with tumor PD‐L1 level of 1% or greater, those receiving N‐I experienced improved PFS (HRN‐I/chemo 0.82, 95% CI 0.69‐0.97) and OS (HRN‐I/chemo 0.79, 95% CI 0.65‐0.96) compared with those receiving chemotherapy (Table 1). This evidence concerns the gene CD274 and neoplasm.